This is an excerpt from the original initial Phase IIb AIPAC results way back in March 25, 2020.
"AIPAC Principal Investigator, Hans Wildiers of University Hospitals Leuven, Leuven, Belgium, said: “I am
pleased to see this innovative chemo-immunotherapy approach in AIPAC is well tolerated by patients, while
showing a numerically (non-significant) higher progression free survival rate compared to chemotherapy
alone."
Which I guess speaks to the statistical significance of these results...
Ann: New & significant data from AIPAC phase 2b trial in MBC, page-9
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.3¢ |
Change
0.003(0.86%) |
Mkt cap ! $428.5M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 29.5¢ | 29.0¢ | $82.67K | 282.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 37 | 362967 | 29.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 174205 | 22 |
View Market Depth
| Last trade - 11.46am 11/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |